US 12,427,057 B2
Controlled drug delivery ocular implants and methods of using same
David S. Haffner, Mission Viejo, CA (US); Thomas W. Burns, Dana Point, CA (US); Harold A. Heitzmann, Irvine, CA (US); and Kenneth M. Curry, Oceanside, CA (US)
Assigned to Glaukos Corporation, Aliso Viejo, CA (US)
Filed by Glaukos Corporation, Aliso Viejo, CA (US)
Filed on Feb. 18, 2022, as Appl. No. 17/651,636.
Application 17/651,636 is a continuation of application No. 15/900,669, filed on Feb. 20, 2018, granted, now 11,253,394.
Application 15/900,669 is a continuation of application No. 14/201,470, filed on Mar. 7, 2014, granted, now 10,206,813, issued on Feb. 19, 2019.
Claims priority of provisional application 61/788,731, filed on Mar. 15, 2013.
Prior Publication US 2022/0233349 A1, Jul. 28, 2022
Int. Cl. A61F 9/00 (2006.01); A61F 9/007 (2006.01)
CPC A61F 9/0017 (2013.01) [A61F 9/00781 (2013.01); A61F 2250/0067 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A drug delivery ocular implant comprising:
an outer shell having a proximal end, a distal end, the outer shell being shaped to define an interior space;
at least one drug positioned within the interior space;
a cap configured for interaction with the proximal end of the outer shell;
a membrane positioned between the cap and the proximal end of the outer shell, wherein the membrane has elastic properties and is permeable or semi-permeable to the at least one drug; and
at least one fluid inflow pathway and at least one fluid outflow pathway, the at least one fluid inflow pathway positioned proximal to the at least one fluid outflow pathway and distal to the at least one drug,
wherein the at least one fluid inflow pathway and one fluid outflow pathway are configured to deliver ocular fluid to a physiological outflow pathway.